NASDAQ:LIVN - LivaNova Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$104.74 +0.78 (+0.75 %)
(As of 06/21/2018 06:00 AM ET)
Previous Close$103.96
Today's Range$101.73 - $105.51
52-Week Range$59.12 - $105.90
Volume345,200 shs
Average Volume528,048 shs
Market Capitalization$5.04 billion
P/E Ratio29.70
Dividend YieldN/A
Beta0.76
LivaNova logoLivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660

Debt

Debt-to-Equity Ratio0.03
Current Ratio1.85
Quick Ratio1.51

Price-To-Earnings

Trailing P/E Ratio29.70
Forward P/E Ratio32.73
P/E Growth3.06

Sales & Book Value

Annual Sales$1.01 billion
Price / Sales5.01
Cash Flow$5.7518 per share
Price / Cash18.21
Book Value$37.65 per share
Price / Book2.78

Profitability

EPS (Most Recent Fiscal Year)$3.31
Net Income$-25,080,000.00
Net Margins-1.99%
Return on Equity9.23%
Return on Assets6.60%

Miscellaneous

Employees4,500
Outstanding Shares48,440,000

LivaNova (NASDAQ:LIVN) Frequently Asked Questions

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) issued its earnings results on Wednesday, May, 2nd. The company reported $0.68 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.03. The company earned $250.40 million during the quarter, compared to the consensus estimate of $245.18 million. LivaNova had a positive return on equity of 9.23% and a negative net margin of 1.99%. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.67 EPS. View LivaNova's Earnings History.

When is LivaNova's next earnings date?

LivaNova is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for LivaNova.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.51.

What price target have analysts set for LIVN?

8 equities research analysts have issued 1-year target prices for LivaNova's stock. Their forecasts range from $50.00 to $115.00. On average, they anticipate LivaNova's stock price to reach $85.4286 in the next year. View Analyst Ratings for LivaNova.

What are Wall Street analysts saying about LivaNova stock?

Here are some recent quotes from research analysts about LivaNova stock:
  • 1. Needham & Company LLC analysts commented, "Wednesday (5/30/18) evening, the Services (CMS) announced that it opened a national coverage analysis (NCA) for vagal nerve stimulation (VNS) for treatment-resistant depression (TRD). LIVN offers the only implantable VNS devices in the US; while its VNS devices are FDA approved for both drug-resistant epilepsy and treatment-resistant depression, CMS currently only covers VNS for drug-resistant epilepsy. We think the most likely outcome of the NCA is the CMS provides coverage with evidence development which would make VNS available to patients enrolled in a registry. LIVN estimates the potential TRD market is ~10x that of drug-resistant epilepsy. We conservatively estimate this opportunity could be worth ~$9 per LIVN share and reiterate our Buy rating." (5/31/2018)
  • 2. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (5/17/2018)
  • 3. Canaccord Genuity analysts commented, "We remain HOLD-rated on shares of LIVN in the wake of their announcement that the company would purchase the remaining part of ImThera – an early-stage company focused on neuromodulation to treat obstructive sleep apnea – that it does not already own. While the technology fits synergistically within LIVN’s strong neuromodulation franchise to some degree, the call point will be different than its current offering (ENTs vs. neurosurgeons). The firm thinks it can leverage its growing OUS neuromodulation sales presence to drive some near-term ImThera revenue (expectations not disclosed) in Europe; however, we expect contributions will be minimal for the next few years at least, primarily on the basis of current reimbursement coverage, or lack thereof, and need for long-term data to catalyze ENT surgeons to adopt the therapy, according to our due diligence." (12/5/2017)

Who are some of LivaNova's key competitors?

Who are LivaNova's key executives?

LivaNova's management team includes the folowing people:
  • Mr. Damien McDonald, Chief Exec. Officer and Director (Age 53)
  • Mr. David S. Wise, Chief Admin. Officer (Age 63)
  • Thad Huston, Chief Financial Officer
  • Mr. Douglas J. Manko, Chief Accounting Officer (Age 44)
  • Ms. Karen King, VP of Investor Relations & Corp. Communications

Has LivaNova been receiving favorable news coverage?

News articles about LIVN stock have been trending somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LivaNova earned a media sentiment score of 0.22 on Accern's scale. They also assigned media coverage about the company an impact score of 45.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.50%), Franklin Resources Inc. (6.63%), Dimensional Fund Advisors LP (3.00%), OppenheimerFunds Inc. (2.49%), Wells Fargo & Company MN (1.85%) and Millennium Management LLC (1.48%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Francesco Bianchi, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova.

Which major investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FIL Ltd, American Century Companies Inc., KBC Group NV, Redmile Group LLC, Dimensional Fund Advisors LP, Epoch Investment Partners Inc. and Bellevue Group AG. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Francesco Bianchi and Hugh M Morrison. View Insider Buying and Selling for LivaNova.

Which major investors are buying LivaNova stock?

LIVN stock was purchased by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Wells Fargo & Company MN, Point72 Asset Management L.P., Rothschild Asset Management Inc., BlackRock Inc., Neuberger Berman Group LLC, Millennium Management LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for LivaNova.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $104.74.

How big of a company is LivaNova?

LivaNova has a market capitalization of $5.09 billion and generates $1.01 billion in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or $3.31 on an earnings per share basis. LivaNova employs 4,500 workers across the globe.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]


MarketBeat Community Rating for LivaNova (LIVN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.